This in combination with the facts that both obesity [13] and fatty liver disease (even after adjustment to BMI) [50,51] are known risk factors for severe COVID-19 disease makes it highly unlikely that the decrease in circulating DPP4 activity in severe COVID-19 could be explained by the higher BMI values. The gene discussed is DPP4; the disease is obesity due to melanocortin 4 receptor deficiency.